PRMT1 and breast neoplasm: Here, the results highlight the potential of PRMT1 as a clinical molecular target to modulate BRCA1 functions after IR and suggest that pharmacological inhibition of this protein or the use of hypomethylating treatments could be therapeutically useful for sensitizing breast tumors to radiotherapy12.